Glaxo Smith Kline

On 19 March we reported on research by the Mayo Clinic into the finanical links of scientists involved in the debate about the diabetes drug Avandia. We should have made clearer that the research concerned the possibility of bias on the part of scientists who have written about Avandia and the need for higher rates of disclosure of financial conflicts of interest, rather than accusing GSK of improperly seeking to influence that debate. We are happy to reiterate, as stated in the article, that GSK is committed to greater transparency and to disclosure of financial links with clinicians.

Comments